Correlation between Serum TNFα and IL6 levels and Severity of Group: A Streptococcal Infections

References

• Choi Y., Lafferty J. A., Clements J. R., Todd J. K., Gelfand E., Kappler J., Marrack P., Kotzin B. Selective expansion of T cells expressing Vb˜2 in toxic shock syndrome. J Exp Med 1990; 172: 981–984
   PubMed Web of Science ®Google Scholar
• Todd J. K. Toxic shock syndrome. Clin Microbiol Rev 1988; 1: 432–436
   PubMedGoogle Scholar
• Cone L. A., Woodard D. R., Schlievert P. M., Tomory G. S. Clinical and bacteriological observations of a toxic-shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317: 146–149
   PubMed Web of Science ®Google Scholar
• Hauser A. R., Stevens D. L., Kaplan E. L., Schlievert P. M. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991; 29: 1562–1567
   PubMedGoogle Scholar
• Holm S. E., Norrby A., Bergholm A-M, Norgren M. Aspects of the pathogenesis of serious group A streptococcal infections in Sweden, 1988–1989. J Infect Dis 1992; 166: 31–37
   PubMedGoogle Scholar
• Musser J. M., Hauser A. R., Kim M. H., Schlievert P. M., Nelson K., Selander R. K. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 1991; 88: 2668–2672
   PubMed Web of Science ®Google Scholar
• Norrby-Teglund A., Pauksens K., Holm S. E., Norgren M. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis 1994; 170: 585–591
   PubMed Web of Science ®Google Scholar
• Stevens D. L., Tanner M. H., Winship J., Swartz R., Ries K. M., Schlievert P. M., Kaplan E. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl Med 1989; 321: 1–7
   PubMed Web of Science ®Google Scholar
• Alouf J. E., Knöll H., Köhler W. The family of mitogenic, shock-inducing and superantigenic toxins from staphylococci and streptococci. Sourcebook of bacterial protein toxins, J. E. Alouf, J. H. Freer. Academic Press, San Diego 1991; 367–414
   Google Scholar
• Fleisher B., Gerardy-Schahn R., Metzroth B., Carrel S., Gerlach D., Köhler W. An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction. J Immunol 1991; 146: 11–17
   PubMedGoogle Scholar
• Janeway C. A., Yagi J., Jr., Conradt P. J., Katz M. E., Jones B., Vroegop S., Buxser S. T-cell responses to Mls and to bacterial proteins that mimics its behaviour. Immunol Rev 1989; 107: 61–88
   PubMed Web of Science ®Google Scholar
• Tomai M., Schlievert P. M., Kotb M. Distinct T cell receptor Vb˜ gene usage by human T lymphocytes stimulated with the streptococcal pyrogenic exotoxins and M protein. Infect Im-mun 1992; 60: 701–705
   PubMedGoogle Scholar
• Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705–711
   PubMed Web of Science ®Google Scholar
• Norrby-Teglund A., Newton D., Kotb M., Holm S. E., Norgren M. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun 1994; 62: 5227–5233
   PubMedGoogle Scholar
• Mollick J. A., Miller G. G., Musser J. M., Cook R. G., Grossman D., Rich R. R. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with amino terminal homol-ogy to staphylococcal enterotoxins B and C. J Clin Invest 1993; 92: 710–719
   PubMedGoogle Scholar
• Tomai M., Kotb M., Majumdar G., Beachey E. H. Superanti-genicity of streptococcal M protein. J Exp Med 1990; 172: 359–362
   PubMed Web of Science ®Google Scholar
• Fleisher B., Schrezenmeizer H., Conradt P. J. T lymphocyte activation by staphylococcal enterotoxins: role of class II molecules and T cell surface structures. Cell 1989; 120: 92–101
   Google Scholar
• Fraser J. D. High affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature 1989; 339: 221–223
   PubMed Web of Science ®Google Scholar
• Mollick J. A., Cook R. G., Rich R. R. Class II MHC molecules are specific receptors for staphylococcus enterotoxin A. Science 1989; 244: 817–820
   PubMed Web of Science ®Google Scholar
• Scholl P., Diez A., Mourad W., Parsonnet J., Geha R. S., Chatila T. Toxic schock syndrome toxin 1 binds to major histocompat-ibility complex class II molecules. Proc Natl Acad Sci USA 1989; 86: 4210–4214
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Imanishi K., Saito S., Araake M., Yan X-J, Fujikawa H., Igarashi H., Kato H., Obata F., Kashiwagi, Inoko H. Activation of human T cells by toxic shock syndrome toxin-1: the toxin binding structures expressed on human lymphoid cells acting as accessory cells are HLA class II molecules. Eur J Immunol 1989; 19: 1803–1809
   PubMedGoogle Scholar
• Kotb M. Role of superantigens in the pathogenesis of infectious diseases and their sequelae. Curr Opin Infect Dis 1992; 5: 364–374
   Google Scholar
• Andersson J., Nagy S., Björk L., Abrams J., Holm S., Andersson U. Bacterial toxin-induced cytokine production studied at the single-cell level. Immunol Rev 1992; 127: 69–96
   PubMed Web of Science ®Google Scholar
• Fast D. J., Schlievert P. M., Nelson R. D. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989; 59: 291–294
   Google Scholar
• Hacket S. P., Stevens D. L. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by mono-cytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992; 165: 879–885
   PubMedGoogle Scholar
• Hackett S. P., Stevens D. L. Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-b˜ synthesis. J Infect Dis 1993; 168: 232–235
   PubMedGoogle Scholar
• Norrby-Teglund A., Norgren M., Holm S. E., Andersson U., Andersson J. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and the pyrogenic exotoxins A and B. Infect Immun 1994; 62: 3731–3738
   PubMedGoogle Scholar
• Norrby A., Norgren M., Holm S. E. Elevated levels of interleukin 6 in serum from patients with serious group A streptococcal infections. Infection 1992; 20: 369–370
   PubMedGoogle Scholar
• Griffith G. The serological classification of Streptococcus pyo-genes. J Hygien 1934; 34: 542–584
   PubMedGoogle Scholar
• Maxted W. R., Widdowson J. P. The protein antigens of group A streptococci. Streptococci and streptococcal diseases, J. W. Wannamaker, J. M. Matsen. Academic Press, New York 1972; 256–261
   Google Scholar
• Peichl P., Ceska M., Effenberger F., Haberhauer G., Broell H., Lindley I. JD. Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol 1991; 34: 333–339
   PubMed Web of Science ®Google Scholar
• Stevens D., Bryant A. E., Hackett S. P. Sepsis syndromes and toxic shock syndromes: concepts in pathogensis and a perspective of future treatment strategies. Curr Opin Infect Dis 1993; 6: 374–383
   Google Scholar
• Schlievert P. M. Role of superantigens in human disease. J Infect Dis 1993; 167: 997–1002
   PubMed Web of Science ®Google Scholar
• Watanabe-Ohnishi R., Low D. E., McGeer A., Stevens D. L., Schlievert P. M., Newton D., Schwartz B., Kreiswirth B. Ontario streptococcal study project, and Kotb M. Selective depletion of Vb˜-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J Infect Dis 1995; 171: 74–84
   PubMedGoogle Scholar
• Jupin C., Andersson S., Damais C., Alouf J. E., Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and γ interferon. J Exp Med 1988; 167: 752–761
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Kamagata Y., Yan X-J, Kohno M., Yoshioko M., Fujikawa M., Igarashi H., Okubo M., Awano F., Saito-Taki T., Nakano M. Study on the biological activities of toxic shock syndrome toxin-1. II. Induction of the proliferative response and the interleukin-2 production by T cells from human peripheral blood mononuclear cells stimulated with the toxin. Clin Exp Immunol 1987; 68: 638–647
   PubMedGoogle Scholar
• Cannon J. G., Tompkines R. G., Gelfand J. A., Michie H. R., Stanford G. G., Van de Meer J. WM, Endres S., Lonneman G., Corsetti J., Chernow B., Wilmore D. W., Wolff S. M., Burke J. F., Dinarello C. A. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79–84
   PubMed Web of Science ®Google Scholar
• Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333–338
   PubMed Web of Science ®Google Scholar
• Müller-Alouf H., Alouf J. E., Gerlach D., Ozegowski J-H, Fitting C., Cavaillon J-M. Comparative study of cytokine release by human peripherial blood mono nuclear cells stimulate with Streptococcal pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. Infect Immun 1994; 62: 4915–4921
   PubMedGoogle Scholar
• Hack S. E., Hart M., Strack van Schijndel R. JM, Eerenberg A. JM, Nuijens J. H., Thijs L. G., Aarden L. A. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992; 60: 2835–2842
   PubMed Web of Science ®Google Scholar